Contrast-Enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
Contrast-enhanced MRI for the Characterization of Ductal Carcinoma in Situ (DCIS)
Sponsor: National Cancer Institute (NCI)
Listed as NCT00804128, this observational or N/A phase trial focuses on Breast Cancer and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 15 times since 2008, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Feb 2024 — Jul 2024 [monthly]
Completed
Status: Recruiting → Completed
-
Oct 2023 — Feb 2024 [monthly]
Recruiting
-
Jan 2023 — Oct 2023 [monthly]
Recruiting
▶ Show 10 earlier versions
-
Jan 2022 — Jan 2023 [monthly]
Recruiting
-
Jun 2021 — Jan 2022 [monthly]
Recruiting
-
May 2021 — Jun 2021 [monthly]
Recruiting
-
Jan 2021 — May 2021 [monthly]
Recruiting
-
May 2020 — Jan 2021 [monthly]
Recruiting
-
Dec 2019 — May 2020 [monthly]
Recruiting
Status: Unknown Status → Recruiting
-
Jun 2018 — Dec 2019 [monthly]
Unknown Status
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: NA → None
-
Feb 2017 — Apr 2018 [monthly]
Unknown Status NA
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status NA
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .